Viking Therapeutics, Inc. (VKTX)
34.16
+0.92
(+2.78%)
USD |
NASDAQ |
Aug 25, 16:00
34.16
0.00 (0.00%)
After-Hours: 17:08
Viking Therapeutics Total Liabilities (Quarterly) : 113.58M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 113.58M |
| March 31, 2026 | 106.32M |
| December 31, 2025 | 76.67M |
| September 30, 2025 | 26.38M |
| June 30, 2025 | 32.39M |
| March 31, 2025 | 20.08M |
| December 31, 2024 | 28.04M |
| September 30, 2024 | 26.44M |
| June 30, 2024 | 25.86M |
| March 31, 2024 | 33.63M |
| December 31, 2023 | 20.07M |
| September 30, 2023 | 14.42M |
| June 30, 2023 | 14.58M |
| March 31, 2023 | 16.83M |
| December 31, 2022 | 23.21M |
| September 30, 2022 | 15.40M |
| June 30, 2022 | 16.28M |
| March 31, 2022 | 12.76M |
| December 31, 2021 | 8.778M |
| September 30, 2021 | 11.35M |
| June 30, 2021 | 12.87M |
| March 31, 2021 | 12.92M |
| December 31, 2020 | 12.16M |
| September 30, 2020 | 9.83M |
| June 30, 2020 | 9.251M |
| Date | Value |
|---|---|
| March 31, 2020 | 8.821M |
| December 31, 2019 | 7.137M |
| September 30, 2019 | 6.63M |
| June 30, 2019 | 6.139M |
| March 31, 2019 | 5.506M |
| December 31, 2018 | 4.562M |
| September 30, 2018 | 4.743M |
| June 30, 2018 | 4.105M |
| March 31, 2018 | 6.339M |
| December 31, 2017 | 8.657M |
| September 30, 2017 | 9.614M |
| June 30, 2017 | 7.733M |
| March 31, 2017 | 7.606M |
| December 31, 2016 | 6.493M |
| September 30, 2016 | 6.098M |
| June 30, 2016 | 5.764M |
| March 31, 2016 | 6.987M |
| December 31, 2015 | 6.714M |
| September 30, 2015 | 5.742M |
| June 30, 2015 | 4.876M |
| March 31, 2015 | 30.61M |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | 25.27M |
| March 31, 2014 | 0.4876M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 7.175B |
| Eli Lilly & Co. | 108.40B |
| Regeneron Pharmaceuticals, Inc. | 10.02B |
| Skye Bioscience, Inc. | 11.53M |
| Eledon Pharmaceuticals, Inc. | 54.06M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 521.90M |
| Shareholders Equity (Quarterly) | 408.32M |
| Debt to Equity Ratio | 0.01 |
| Current Ratio | 4.720 |
| Net Debt Paydown Yield | -0.01% |